B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders

被引：16

作者：

Stuegen, Joerg-Patrick ^{[1
]}

机构：

[1] Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York Presbyterian Hosp, New York, NY 10065 USA

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2008年 / 204卷 / 1-2期

关键词：

B cell depletion; Rituximab; Autoimmune polyneuropathy; Myasthenia gravis; Inflammatory myopathy;

D O I：

10.1016/j.jneuroim.2008.07.019

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

B lymphocytes play a central role in the pathogenesis of autoimmunity, so that B cell suppression is considered a potential treatment option for immune-mediated diseases. Rituximab, a chimeric anti-human CD20 antibody, is the only anti-B cell biological agent presently under study for the treatment of autoimmune neuromuscular diseases. Isolated case histories and series, pilot and retrospective studies report on the experimental administration of rituximab as treatment of a variety of immune-mediated neuropathy syndromes, treatment-refractory myasthenia gravis and inflammatory myopathies. Rituximab was used as monotherapy or in combination with other types of immunomodulation, and was well tolerated. The mechanism whereby B cell depletion shows benefit is uncertain and may vary depending on the inherent differences in the pathogenesis of various autoimmune neuromuscular disorders. (C) 2008 Elsevier B.V. All rights reserved.

引用

页码：1 / 12

页数：12

共 159 条

[1]

Abbas A K., 2005, Cellular and Molecular Immunology, VFitth, P1

[2]

Alas S, 2001, CANCER RES, V61, P5137

[3] Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons:: depletion of CD20-and CD22-positive B cells does not result in significantly decreased production of anti-αGal antibody [J].